BCYC Bicycle Therapeutics
- 20.210
- +0.190+0.95%
- 20.210
- 0.0000.00%
Bicycle Therapeutics News
HC Wainwright & Co. : The Bicycle Therapeutics (BCYC.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $55.00.
Bicycle Therapeutics Analyst Ratings
Barclays Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)
Bicycle Therapeutics: Strong Q1 Performance and Promising Clinical Trials Drive Buy Rating
Analysts' Top Healthcare Picks: Lantheus (LNTH), Bicycle Therapeutics (BCYC)
Analysts Conflicted on These Healthcare Names: Tilray (TLRY), Hologic (HOLX) and Bicycle Therapeutics (BCYC)
Needham: Reiterates Bicycle Therapeutics (BCYC.US) rating and adjusted from buy to buy rating, target price is $43.00.
Bicycle Therapeutics Analyst Ratings
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $43 Price Target
Analysts Are Bullish on These Healthcare Stocks: Edgewise Therapeutics (EWTX), Bicycle Therapeutics (BCYC)
HC Wainwright & Co. Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $55
Analysts Are Bullish on These Healthcare Stocks: Bicycle Therapeutics (BCYC), Tactile Systems Technology (TCMD)
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $43 Price Target
Bicycle Therapeutics Analyst Ratings
Bicycle Therapeutics (BCYC) Receives a Buy From JMP Securities
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), GeneDx Holdings (WGS) and Halozyme (HALO)
Analysts Conflicted on These Healthcare Names: Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
JMP Securities Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $32
Bicycle Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Reneo Pharmaceuticals (RPHM) and Bicycle Therapeutics (BCYC)
Analysis
Price Target
No Data
